Health Care · Pharmaceutical Preparations

SEPN Septerna, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 198408659 filings
Russell 2000

SEPN at a glance

Septerna, Inc. (SEPN, SEC CIK 1984086) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Septerna, Inc. (SEPN) reported revenue of $46.0 million (up 4174.5% from FY2024) and a net loss of $48.9 million. Diluted EPS was -$1.10.
  • As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Septerna, Inc. (SEPN) shares worth $349.0 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Labrucherie Gil M on November 16, 2026 of 3,485 shares at $41.99 per share.
  • In the last 90 days, SEPN insiders reported 0 open-market purchases ($0) and 18 open-market sales ($5.8M) on Form 4, a net sale of $5.8M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$46.0M
+4174.5% vs prior year
Insiders · 90 days
0 buys · 18 sells
Net −$5.8M
13F holders
25 funds
$349.0M · +0 vs prior quarter
Latest 8-K
Nov 9, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $18.9M, down $2.6M YoY from $21.5M, including $13.2M cumulative catch-up reduction
  • Net loss $26.6M vs $8.2M net income YoY, operating loss $27.2M vs $2.6M income
  • R&D spending $36.6M, up $12.3M YoY, led by other discovery/preclinical programs at $7.2M
  • Cash, equivalents and marketable securities $565.2M, funding operations into mid-2029
  • ATM proceeds $61.0M; operating cash use $61.6M through nine months, SEP-479 data expected first quarter 2027

Risk Factors

  • Newly added development risk: SEP-204 selected as a development candidate in November 2026, expanding preclinical execution demands
  • Regulatory risk: June 2026 FDA draft guidance permits one pivotal trial with confirmatory evidence, but FDA may still require a second trial
  • Clinical safety risk: SEP-786 discontinued after two unanticipated Grade 3 elevated unconjugated bilirubin events
  • Financial risk: $565.2 million in cash, equivalents and marketable securities expected to fund operations into mid-2029
  • Trade and supply-chain risk: BIOSECURE Act restrictions could disrupt reliance on China-based CDMOs, including WuXi

AI summary of the SEPN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 results and business highlights announced for the quarter ended September 30, 2026
  • Detailed financial figures and operating updates available in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • Q3 2026 revenue $18.9M, including $5.2M milestone revenue and $11.0M Novo research services
  • Net loss $26.6M versus $8.2M net income, reflecting higher R&D expense of $36.6M
Filed Nov 4, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • SEP-204 selected as development candidate for Graves’ disease and thyroid eye disease
  • Preclinical SEP-204 data reported at the 2026 American Thyroid Association Annual Meeting

Item EX-99.1: Item EX-99.1

  • SEP-204 selected as potential first-in-class oral TSHR NAM for Graves’ disease and thyroid eye disease
  • Preclinical models showed normalized T4, reduced thyroid enlargement and reduced orbital proptosis

Item EX-99.2: Item EX-99.2

  • SEP-479 Phase 1 SAD/MAD data anticipated Q1 2027, with observed 3-4 day half-life supporting once-daily dosing
  • SEP-204 Phase 1 initiation anticipated Q1 2027 for Graves’ disease and thyroid eye disease
Filed Aug 25, 2026Full analysis →

Item 8.01: Other Events

  • Rajiv Patni, M.D. appointed Chief Medical Officer effective August 24, 2026
  • Senior leadership addition relevant to Septerna’s clinical-development strategy and medical oversight

Item 7.01: Regulation FD Disclosure

  • Septerna appointed Rajiv Patni, M.D., an industry veteran, as Chief Medical Officer
  • Leadership change adds senior clinical development expertise, potentially supporting pipeline advancement and regulatory execution

AI summaries of SEPN 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for SEPN

Don't miss the next SEPN filing

  • Alerts as it files. A push when SEPN files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut SEPN, by share count.
  • Ask anything. An AI agent that reads every SEPN filing and answers with sources.

SEPN alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Labrucherie Gil MSellNov 16, 2026$41.99
Labrucherie Gil MSellNov 16, 2026$41.48
Labrucherie Gil MSellNov 16, 2026$43.00
Finer JeffreySellNov 12, 2026$42.09
Finer JeffreySellNov 12, 2026$46.16
Finer JeffreyMNov 12, 2026$2.76
Finer JeffreySellNov 12, 2026$44.23
Finer JeffreySellNov 12, 2026$43.10

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$151K$1.1M$46.0M
Operating Income--$80.8M-$68.3M
Net Income--$71.8M-$48.9M
Op. Margin--7518.4%-148.6%
Net Margin--6678.9%-106.4%
Balance Sheet
Total Assets$130.9M$456.6M$596.2M
Equity-$38.4M$420.0M$381.9M
ROE--17.1%-12.8%
Per Share
EPS$0.29$-7.26$-1.10
Cash Flow
Operating CF--$67.5M$110.2M
CapEx-$2.1M$518K

Source: XBRL data in Septerna, Inc. (SEPN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate SEPN share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
SEPN shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202625$349.0M
Q2 202625$275.0M
Q1 202621$182.6M
Q4 202521$209.7M
Q3 202519$111.4M
Q2 202519$56.1M
Q1 202515$21.5M
Q4 202412$66.7M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 157 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

SEPN filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
4Nov 16, 2026--
4Nov 13, 2026--
8-KNov 9, 2026Analysis-
10-QNov 9, 2026Analysis
8-KNov 4, 2026Analysis-
4Oct 19, 2026--
4Sep 10, 2026--
4Sep 3, 2026--
8-KAug 25, 2026Analysis-
4Aug 14, 2026--
4Aug 14, 2026--
4Aug 13, 2026--
10-QAug 10, 2026Analysis
8-KAug 10, 2026Analysis-
4Aug 5, 2026--
4Jul 17, 2026--
4Jun 30, 2026--
4Jun 30, 2026--
4Jun 30, 2026--
8-KJun 30, 2026Analysis-
4Jun 30, 2026--
4Jun 30, 2026--
4Jun 30, 2026--
4Jun 30, 2026--

Related Health Care companies

All Health Care →

SEPN SEC filings: frequently asked questions

Are SEPN insiders buying or selling?

In the last 90 days, Septerna, Inc. (SEPN) officers, directors and 10% owners reported no open-market purchases and 18 open-market sales worth $5.8 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold SEPN stock?

As of September 30, 2026, the largest Septerna, Inc. (SEPN) holders among the 13F filers tracked by SignalX were Goldman Sachs Group ($118.1 million), BlackRock ($81.2 million), Vanguard Capital Management LLC ($53.0 million), State Street Corp ($31.2 million), Vanguard Portfolio Management LLC ($9.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was SEPN's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Septerna, Inc. (SEPN) reported revenue of $46.0 million (up 4174.5% from FY2024) and a net loss of $48.9 million. Diluted EPS was -$1.10. The figures come from the XBRL data in the 10-K.

What did SEPN report in its latest 8-K?

Septerna, Inc. (SEPN) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 results and business highlights announced for the quarter ended September 30, 2026.

What are the latest SEPN SEC filings?

Septerna, Inc. (SEPN) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 18, 2026.

What is SEPN's SEC CIK number?

Septerna, Inc. (SEPN)'s SEC Central Index Key (CIK) is 1984086. EDGAR lists every SEPN filing under that number.

Ask anything about SEPN

The research agent reads SEPN's filings, financials, insider trades and 13F holders, then answers with sources.